Minerva Neurosciences
NERV
23 hedge funds and large institutions have $7.51M invested in Minerva Neurosciences in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 13 closing their positions.
65% more call options, than puts
Call options by funds: $311K | Put options by funds: $189K
36.74% more ownership
Funds ownership: 5.76% → 42.5% (+37%)
30% less funds holding
Funds holding: 33 → 23 (-10)
40% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 10
54% less capital invested
Capital invested by funds: $16.3M → $7.51M (-$8.83M)
77% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$34.4K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$24K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$14.1K |
| 4 |
Citigroup
New York
|
+$8.68K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.91K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$850K |
| 2 |
Millennium Management
New York
|
-$77.1K |
| 3 |
D.E. Shaw & Co
New York
|
-$76K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$54K |
| 5 |
Renaissance Technologies
New York
|
-$53.7K |
NERV Hedge Fund Activity: Q2 2022 in Review
23 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Minerva Neurosciences (NERV) for Q2 2022, worth a combined $7.51M — down 54% from $16.3M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of NERV and 3 opened new positions — a net loss of 10 holders — while 10 trimmed existing stakes and 6 added.
The largest buyer was Barclays, opening a new position worth an estimated $34.4K. The largest seller was Armistice Capital, exiting entirely with an estimated $850K sold.
- 23 institutional investors held Minerva Neurosciences (NERV) as of Q2 2022, down from 33 in Q1 2022.
- Funds reported $7.51M of Minerva Neurosciences stock for Q2 2022, down 54% quarter-over-quarter.
- 3 funds opened new Minerva Neurosciences positions in Q2 2022 and 13 closed out, a net change of -10 holders.
- The largest Minerva Neurosciences buyer in Q2 2022 was Barclays, an estimated $34.4K added.
- The largest Minerva Neurosciences seller in Q2 2022 was Armistice Capital, an estimated $850K sold.
Based on aggregated 13F filings for Q2 2022.